Brief: Immuneering To Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling And Safety Data For Universal-Ras Program Imm-1-104 At American Association For Cancer Research Annual Meeting 2023
05/04/2023 13:49
April 5 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING TO PRESENT INITIAL PHASE 1 PHARMACOKINETIC,
PHARMACODYNAMIC MODELING AND SAFETY DATA FOR UNIVERSAL-RAS
PROGRAM IMM-1-104 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH
ANNUAL MEETING 2023
Source text for Eikon: ID:nGNX7S8F7r
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences